Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

 

• Anixa Biosciences (ANIX +4.5%) has entered into a license agreement with Cleveland Clinic for exclusive, world-wide rights to an ovarian cancer vaccine technology. The development-stage vaccine targets the extracellular domain of anti-mullerian hormone receptor 2 (AMHR2-ED), that appears in many types of ovarian cancer.
• Anixa and Cleveland Clinic are already collaborating on a preventative breast cancer vaccine, and human trials are expected to commence in early next year.
• https://seekingalpha.com/news/3640425-anixa-biosciences-cleveland-clinic-in-ovarian-cancer-vaccine-pact